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Abstract
Background: There is a strong association between factor VIII (FVIII) and presence of
cardiovascular disease (CVD). Exercise is a known trigger for myocardial infarction, and
the majority of ischemic events from physical stress occur due to an occlusive thrombus.
FVIII increases acutely with exercise and remains elevated hours after exercise.
Furthermore, FVIII is also higher in cigarette smokers, however, it has not been
investigated in e-cigarette smokers. The purpose of this study is to identify potential
differences in FVIII before exercise, after exercise, and its magnitude of change in ecigarette users versus non-users.
Methods: Eighteen individuals (8 e-cigarette users, 3 women and 5 men, and 10 nonsmokers, 7 women and 3 men; age, 18-32 years old) were recruited to participate in this
research study. An incremental test to exhaustion (x̄=12.20 ± 3.20 minutes) was
performed on an electronically braked cycle ergometer (Lode Corival cpet; Groningen,
Netherlands) to determine the peak rate of oxygen consumption (VO ). Ten mL of
2peak

blood was drawn into a citrate anticoagulant solution from an antecubital vein using clean
venipuncture with minimal stasis both prior to and immediately following exercise
testing. A commercially available ELISA kit was used to determine plasma
concentrations of coagulation FVIII antigen.
Results: There was no significant difference between smokers (N = 8, 4.35 ± 2.09 IU/ml)
and nonsmokers (N = 9, 5.02 ± 4.87 IU/ml, p=0.72) for resting FVIII antigen. There was
a main effect for exercise in that the post-exercise values (N=10, 7.76 ±1.40 IU/ml) were
larger than pre-exercise values (N=10, 3.82 ± 0.65, p=0.003). However, there was no
main effect for smoking and no smoking x exercise interaction (post-exercise smokers,
N=4, 6.67 ± 1.46, post-exercise non-smokers, N= 7, 8.39 ± 5.81, p=0.58).
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Conclusion: Our preliminary data suggests that e-cig use does not significantly affect
FVIII or the FVIII response to exercise.
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Chapter I
Introduction
Clinical Importance of Hemostasis
Cardiovascular disease (CVD) is the leading cause of death in the United States,
manifesting itself through ischemic events like myocardial infarction and stroke (13). A
majority of these events are caused by plaque ruptures that form a clot inside either the
plaque or the lumen of a blood vessel, leading to blockage of blood flow in the artery.
There is autopsy evidence of atherosclerotic plaques in people without any history of
myocardial infarction (16,44), suggesting plaque rupture alone is not sufficient to cause
an ischemic event and must occur in combination with prothrombotic conditions.
Therefore, blood coagulation and clot dissolution (or fibrinolysis) are clinically relevant.
There is a strong association between coagulation and presence of CVD. In
particular, fibrinogen is associated with CVD and related ischemic events. As a substrate
converted to fibrin clot, fibrinogen promotes coagulation by enhancing platelet
aggregation (38) and is linked with risk for CVD (20,46) coronary artery disease (CAD)
(58), myocardial infarction (58,1), stroke (1), and mortality (1) in patients with CVD.
Other important markers for blood coagulation include factors VII (FVII), and VIII
(FVIII), von Willebrand Factor (vWF), and thrombin-antithrombin complex (TAT), a
marker for thrombin formation. Like fibrinogen, all of these markers of coagulation
potential are also associated with the presence of CVD (46), CAD (51), myocardial
infarction (29), stroke (12), and mortality (12) in patients with CVD. Increased
coagulation potential may also increase the progression of atherosclerosis, with higher
rates of hypercoagulation in patients with peripheral artery disease (PAD)
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(50). However, coagulation potential is not the only factor impacting risk of ischemic
events.
There is also a strong connection between decreased fibrinolysis and the presence
of CVD. The main enzyme involved in fibrinolysis is tissue plasminogen activator (tPA),
which catalyzes the conversion of plasminogen to plasmin, resulting in fibrinogen
dissolving into fibrin dimer proteins. The most prominent inhibitor of tPA is plasminogen
activator inhibitor-1 (PAI-1), which binds to tPA and inhibits its function. Increases in
PAI-1 and decreases in tPA activity are both associated with CVD (37), CAD (47),
ischemic events (58), stroke (34), and mortality (30). The degree of impairment in the
fibrinolytic potential also impacts the progression of PAD, with significantly lower tPA
activity in patients with severe claudication compared to those with mild claudication
(37). Furthermore, impaired fibrinolysis is independently associated with risk factors for
CVD, like body composition (36), hyperlipidemia (29,31) diabetes mellitus, body mass
index, low-density lipoprotein (36).
Coagulation Responses to Exercise
Exercise is a known trigger for myocardial infarction in roughly one-third of
patients who can identify a trigger (59). Furthermore, ischemic events resulting from
physical stress occur due to an occlusive clot more frequently than events unrelated to
physical stress (22). Thus, coagulation and fibrinolytic responses to exercise have
important clinical implications.
Activated partial thromboplastin (APTT), a measure of the intrinsic and common
pathway of coagulation, significantly decreases following exercise across sexes (7,25)
and exercise modalities (52,60). However, this acute effect is not consistently seen on
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prothrombin time (PT), with studies reporting both shortened (25) and unchanged (52)
PTs after acute exercise. These inconclusive findings suggest that the extrinsic tissue
factor pathway are not as involved in exercise-induced hemostatic responses (63).
FVIII activity (FVIII:c) and FVIII antigen (FVIII:ag) increase acutely with
exercise and remain elevated hours after exercise (4,61), with the magnitude of both
responses being dependent on exercise intensity (41). Other markers, including TAT,
prothrombin fragments 1 and 2 and fibrinopeptide A are increased following 1-hour of
high intensity exercise but not following a moderate-intensity exercise of the same
duration (64). There are no acute effects of exercise on FVII, with no observed changes
in FVII:c following maximal exercise (60,61), no change in FVII:ag, FVII:ag/FVII:c
ratio, and plasma concentrations of circulating activated FVII following exhaustive
exercise (63).
Although the specific mechanisms are uncertain, increased beta-adrenergic
activity influences the coagulation response to exercise, as B-adrenergic blockade inhibits
the exercise-induced increases in FVIII (14). Furthermore, platelet activation increases
following an infusion of epinephrine or norepinephrine (26,39,40). Another mechanism
influencing the coagulation response to exercise is endogenous NO production. When
partially blocking NO production, the exercise induced response in the vWF and FVIII is
inhibited (32). Despite markers for coagulation increasing following acute exercise,
results for fibrinogen are inconclusive with evidence showing both increases (4),
decreases (6), and no change (23) in fibrinogen levels following acute exercise.
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Fibrinolytic Responses to Exercise
Overall, fibrinolysis increases as a result of acute exercise due to increases in tPA
activity paired with reductions in PAI-1 activity. Mechanistically, these fibrinolytic
responses during exercise are due to an increased release of tPA from vascular
endothelial cells (41). This mechanism occurs through hypoglycemia as well as increases
in 1-deamino-8-D-arginine-vasopressin, epinephrine, and thrombin; all of which occur
during acute exercise (49). This increase in tPA may be large enough to effectively
reduce PAI-1 activity as PAI-1 forms an inactive, irreversible bond with tPA.
These fibrinolytic responses are magnified with increases in intensity. Streiff and
Bell (57) reported significant increases in fibrinolysis do not usually occur until
individuals reach 50% of their max heart rate (HR). With there being a proposed
threshold intensity of 80-90% max HR for exponential changes in fibrinolytic activity to
occur (17). The threshold-like exercise response pattern for epinephrine could explain
these findings in fibrinolytic activity (42). However, Womack et al. (65) reported
fibrinolytic responses below lactate threshold, with intensities above lactate threshold
eliciting greater fibrinolytic responses. Duration can influence the fibrinolytic responses,
but to a lesser degree than does intensity, as Womack et al. observed higher intensity
exercise at a duration of 20 minutes leads to greater fibrinolytic responses than does
moderate intensity, equicaloric work at a moderate intensity.
The Effects of Smoking/Nicotine on Hemostasis
Both direct and second-hand exposure to cigarette smoking decreases Nitric
Oxide (NO) availability by altering the expression and activity of the endothelial NO
synthase enzyme (3). Mechanistically, cigarette smoke contains high amounts of free
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radicals that lead to the reduced bioavailability of NO. NO plays both a direct and
indirect role in thrombosis by inhibiting platelet adhesion and aggregation and increasing
platelet recruitment (28,53). Impaired NO bioavailability results in secretion of
thromboxane A2 from the platelets, thus enhancing platelet aggregation (33). Exposure to
cigarette smoke increases vWF and fibrinogen, contributing to this process and enhancing
thrombosis.
Higher plasma levels of fibrinogen and viscosity are the main contributors to
higher coagulability found in smokers (43). Lifetime duration of smoking is a
determinant of baseline fibrinogen levels; however, these levels quickly drop following
smoking cessation. Cigarette smokers have significantly higher plasma fibrinogen than
non-smokers (45,62,35), while pipe-cigar smokers show no significant difference from
non-smokers (62). When these individuals were split into lighter (1-19 cigarettes/day)
and heavier (20+ cigarettes/day) categories, heavier smokers had higher levels of
fibrinogen (62). This increase is not unique to cigarette smoking, however, as hookah
smokers have higher plasma fibrinogen in comparison to both non-smokers and cigarette
smokers (54).
Fibrinolysis is also impaired by cigarette usage, as tPA production and release
being significantly lower in smokers compared to nonsmokers despite no significant
difference in PAI-1 activity (8). Pretorius et al. observed smokers exhibited a reduced
tPA release compared to non-smokers when stimulated with bradykinin, a stimulant for
tPA release (48).
There is no evidence that nicotine, the most integral ingredient found in cigarettes,
has any effect on hemostasis. Oral and transdermal nicotine studies have found no
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significant chronic influence on hemostatic markers in healthy adults (10). This would
suggest the main cause for chronic hematological changes from smoking are caused by
other ingredients embedded in the cigarette.
There is evidence from both epidemiological and experimental studies that
particulate matter (PM), such as black carbon, nitrogen dioxide, and carbon monoxide,
results in hypercoagulability and hypofibrinolysis. Plasma fibrinogen has been one of the
most studied variables in both prospective cohort and experimental studies, with evidence
suggesting increased fibrinogen levels from PM and ambient particles in concentrated
doses (9,27,55). There is, however, no clear pattern for other pro-coagulant variables
such as prothrombin time (PT), PAI-1, and tPA, which all have equivocal results
(5,11,18,19).
Very few studies have analyzed associations between individual PM constituents
and changes in biomarkers of hemostasis. However, particle mass influences the
hemostatic response, with no statistically significant changes from pre exposure for
prothrombin, fibrinogen, FVII, FVIX, vWF, PAI-1, plasminogen, tPA, or fibrin d-dimer
at 1 hour or at 20 hours after exposure to coarse air particles and a statistically significant
increase in all of those variables after exposure to fine air particles (56). These fine
particles are transmitted in concentrated doses while smoking cigarettes. However, the
main ingredients in Juuls, propylene glycol and glycerine, have not been examined in
humans for their hematologic effects.
Purpose
The purpose of this study is to identify potential differences in hemostatic variables both
before and after exercise in e-cigarette users versus non-users.
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Hypothesis
Resting differences of hemostasis will persist in e-cigarette users immediately following
acute, maximal exercise.
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Chapter II
Methodology
Subjects
Forty individuals will be recruited to participate in this research study (20 ecigarette users and 20 non-smokers). Subjects will be college-aged (18-35 years of age),
healthy, and never diagnosed with pulmonary, metabolic, cardiovascular or renal disease.
The subjects will be matched for physical activity (pa) level between experimental (ecigarette users) and the control group (non-smokers) using the long version of the
International Physical Activity Questionnaire (IPAQ). E-cigarette users will be defined as
actively smoking e-cigarettes at least 4 days a week. Non-smokers will be defined as not
having smoked any form of tobacco or marijuana over the past 6 months. Participants
will be recruited through on campus flyers, a bulk e-mail request to all James Madison
University faculty and students, and from surrounding areas in the Harrisonburg
community. Subjects will be excluded if they have any signs or symptoms of
cardiovascular or metabolic disease, or are asymptomatic but have previously been
diagnosed with disease. Subjects will also be excluded if they are on any medication that
could alter their hemostatic variables. Transdermal nicotine or chewing tobacco use will
be permitted, but the Tobacco Use Questionnaire will be used to screen for and exclude
combustible tobacco and marijuana usage and baseline testing will be performed to
confirm subjects’ exhaled carbon monoxide (eCO) < 4 parts per million (ppm). All
methods received IRB approval and informed consent will be obtained from all subjects
prior to testing.
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Study Design
All testing will be done before 10:00 am, to control for diurnal influences on the
variables under examination (2). Subjects will abstain from caffeine and alcohol for 24
hours before each visit, and have no food or drink other than water for 12 hours before
their visit. In addition, subjects will be required to refrain from smoking for 3 hours and
exercise for 24 h before their laboratory visit. Lastly, subjects will be excluded from
participation if they have any flu or fever symptoms within one week of their lab
sessions.
Blood Sampling Assays
Subjects will assume a semi-recumbent position prior to and following exercise
testing, 10 mL of blood will be drawn into a citrate anticoagulant solution from an
antecubital vein using clean venipuncture with minimal stasis. Blood samples will be
immediately centrifuged for 20 min at 1500g and 4-C to obtain platelet-poor plasma.
Plasma aliquots will be frozen and stored at -80 degrees C until assayed. Commercially
available ELISA kits will be used to determine plasma concentrations of coagulation
FVIII antigen (VisuLize; Ontario, Canada), fibrinogen (Eagle Bioscience, Inc; Nashua,
NH), active tPA (Eagle Bioscience, Inc; Nashua, NH), tPA antigen (Eagle Bioscience,
Inc), and active PAI-1(Eagle Bioscience, Inc).
Incremental Exercise Test
An incremental test to exhaustion (12-15 minutes) will be performed on an
electronically braked cycle ergometer (Lode Corival cpet; Groningen, Netherlands) to
determine the peak rate of oxygen consumption (VO ). Resting metabolic measurements
2peak

will be taken for 3 minutes prior to starting the test. Participants will then begin to warm-
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up for approximately 2 minutes at a work rate of 60 watts, always keeping the cadence
above 50 revolutions per minute (rpm). Work rate will increase by 10 watts per minute
for females and 20 watts per minute for males. Ventilatory and metabolic data will be
recorded via a Vmax metabolic measuring system (Carefusion; San Diego, CA). Heart
rate will be recorded during the test with a PolarLink heart rate monitor and chest strap.
The test will be terminated when the subject reaches volitional exhaustion or when they
can no longer maintain 50 rpm. Blood samples will be obtained again within two minutes
of exercise cessation (15).
Accelerometer
Individuals will be asked to wear an Actigraph GT3X accelerometer for seven
days to objectively measure their moderate-to-vigorous physical activity (MVPA). The
participants will wear the accelerometers at all times, except while sleeping and
showering. Freedson cut points will be used to quantify the amount of physical activity
participants obtain per week (21). Participants will also be asked to keep a log of nonwear time and report when they put the accelerometer on in the morning and when they
take the accelerometer off at night. Subjects must wear the accelerometer for a minimum
of 13 hours a day for the data to count (24).
Statistical Analysis
FVIII antigen, fibrinogen, active tPA, tPA antigen, and active PAI-1 will be
analyzed using repeated measures analysis of variance with exercise as the withinsubjects factor and smoking status as the between-subjects factor. Post hoc comparisons
will be made using Fisher’s LSD test. A priori statistical significance will be set at P <
0.05.
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Abstract
Background: There is a strong association between factor VIII (FVIII) and presence of
cardiovascular disease (CVD). Exercise is a known trigger for myocardial infarction, and
the majority of ischemic events from physical stress occur due to an occlusive thrombus.
FVIII increases acutely with exercise and remains elevated hours after exercise.
Furthermore, FVIII is also higher in cigarette smokers, however, it has not been
investigated in e-cigarette smokers. The purpose of this study is to identify potential
differences in FVIII before exercise, after exercise, and its magnitude of change in ecigarette users versus non-users.
Methods: Eighteen individuals (8 e-cigarette users, 3 women and 5 men, and 10 nonsmokers, 7 women and 3 men; age, 18-32 years old) were recruited to participate in this
research study. An incremental test to exhaustion (x̄=12.20 ± 3.20 minutes) was
performed on an electronically braked cycle ergometer (Lode Corival cpet; Groningen,
Netherlands) to determine the peak rate of oxygen consumption (VO ). Ten mL of
2peak

blood was drawn into a citrate anticoagulant solution from an antecubital vein using clean
venipuncture with minimal stasis both prior to and immediately following exercise
testing. A commercially available ELISA kit was used to determine plasma
concentrations of coagulation FVIII antigen.
Results: There was no significant difference between smokers (N = 8, 4.35 ± 2.09 IU/ml)
and nonsmokers (N = 9, 5.02 ± 4.87 IU/ml, p=0.72) for resting FVIII antigen. There was
a main effect for exercise in that the post-exercise values (N=10, 7.76 ±1.40 IU/ml) were
larger than pre-exercise values (N=10, 3.82 ± 0.65, p=0.003). However, there was no
main effect for smoking and no smoking x exercise interaction (post-exercise smokers,
N=4, 6.67 ± 1.46, post-exercise non-smokers, N= 7, 8.39 ± 5.81, p=0.58).
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Conclusion: Our preliminary data suggests that e-cig use does not significantly affect
FVIII or the FVIII response to exercise.
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Introduction
Cardiovascular disease (CVD) is the leading cause of death in the United States,
manifesting itself through ischemic events such as myocardial infarction and stroke (9).
There is a strong association between coagulation and presence of CVD. In particular,
fibrinogen and factor VIII (FVIII), promote coagulation and are linked with risk for CVD
(12,24), coronary artery disease (CAD) (26,29), myocardial infarction (1,16,29), stroke
(1,8), and mortality (1,8) in patients with CVD.
Exercise is a known trigger for myocardial infarction (30), and the majority of
ischemic events from physical stress occur due to an occlusive thrombus (13). FVIII
increases acutely with exercise and remains elevated hours after exercise (3,31). FVIII is
also elevated in cigarette smokers (17), with CVD risk increasing as fibrinogen levels
increase (18). This may be due to increased inflammation from inhaling particulate
matter (PM) as inhalation of wood smoke results in acute increases in FVIII (5) and the
inflammatory cytokine IL-6 has been linked to FVIII (33). In contrast, oral and
transdermal nicotine use does not chronically influence hemostatic markers in healthy
adults (7). This suggests the main cause for chronic hematological changes from smoking
are caused by other PM embedded in the cigarette, such as black carbon, nitrogen
dioxide, and carbon monoxide which are all transmitted in concentrated doses in
cigarettes. The evidence also suggests increased fibrinogen levels from PM and ambient
particles in concentrated doses (6,15,28).
Recently, e-cigarette smoking has surged in young adults; increasing by 78%
among high school students from 2017 to 2018 (11). However, the main ingredients in
Juuls®, propylene glycol and glycerine, have not been examined in humans for their
hematologic effects. Furthermore, the hematologic response before and after exercise in
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e-cigarette smokers has not been clearly identified. The purpose of this study is to
identify potential differences in FVIII both before and after exercise in e-cigarette users
versus non-users.
Methodology
Subjects
Eighteen individuals were recruited to participate in this research study (8 ecigarette users and 10 non-smokers, see Table 1 for demographic characteristics).
Subjects were free from known pulmonary, metabolic, cardiovascular or renal disease. Ecigarette users were defined as actively smoking e-cigarettes at least 4 days a week. Nonsmokers were defined as not having smoked any form of tobacco or marijuana over the
past 6 months. Participants were recruited through on campus flyers, a bulk e-mail
request to all James Madison University faculty and students, and from the surrounding
Harrisonburg community. Subjects were also excluded if they were on any medication
that could alter hemostatic variables (such as aspirin or anti-coagulants). Transdermal
nicotine or chewing tobacco use was permitted in the smoking group, but the Tobacco
Use Questionnaire was used to screen for and exclude combustible tobacco and
marijuana usage and baseline testing was performed to confirm subjects’ exhaled carbon
monoxide (eCO) < 4 parts per million (ppm). All methods received IRB approval and
informed consent was obtained from all subjects prior to testing.
Study Design
All testing was done before 10:00 am, to control for diurnal influences on
hemostasis (2). Subjects abstained from caffeine and alcohol for 24 hours before each
visit and had no food or drink other than water for 12 hours before their visit. In addition,
subjects were required to refrain from smoking for 3 hours and exercise for 24 hours
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before their laboratory visit. Lastly, subjects were excluded from participation if they had
any flu or fever symptoms within one week of their lab sessions.
Blood Sampling Assays
Subjects assumed a semi-recumbent position prior to and following exercise
testing. Ten mL of blood was drawn into a citrate anticoagulant solution from an
antecubital vein using clean venipuncture with minimal stasis. Blood samples were
immediately centrifuged for 20 min at 1500g and 4-C to obtain platelet-poor plasma.
Plasma aliquots were frozen and stored at -80 degrees C until assayed. A commercially
available ELISA kit was used to determine plasma concentrations of coagulation FVIII
antigen (VisuLize; Ontario, Canada). For the FVIII antigen assay, several samples were
higher than the highest standard used in the ELISA plate. Despite the manufacturer’s
recommendations, we calculated FVIII for these samples from the standard curve that
was generated. We successfully obtained pre-exercise blood samples for 8 smokers and 9
nonsmokers and post exercise blood samples for 4 smokers and 7 nonsmokers.
Incremental Exercise Test
An incremental test to exhaustion (12-15 minutes) was performed on an
electronically braked cycle ergometer (Lode Corival cpet; Groningen, Netherlands) to
determine the peak rate of oxygen consumption (VO ). Resting metabolic
2peak

measurements were taken for three minutes prior to starting the test. Participants then
began to warm-up for approximately two minutes at a work rate of 60 watts, always
keeping the cadence above 50 revolutions per minute (rpm). Work rate was increased by
10 watts per minute for females and 20 watts per minute for males. Ventilatory and
metabolic data was recorded via a Vmax metabolic measuring system (Carefusion; San
Diego, CA). Heart rate was recorded during the test with a PolarLink heart rate monitor
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and chest strap. The test was terminated when subjects reached volitional exhaustion or
when they could no longer maintain 50 rpm. Blood samples were obtained again within
two minutes of exercise cessation (10).
Statistical Analysis
We performed an independent t-test to compare resting FVIII antigen for the two
groups. For the exercise response, we performed a repeated measures analysis of
variance with exercise (pre, post) as the within-subjects factor and smoking status
(smoker, non-smoker) as the between-subjects factor. A priori statistical significance
was set at P < 0.05.
Results
For the baseline comparison of FVIII antigen, there was no significant difference
between smokers (N = 8, 4.35 ± 2.09 IU/ml) and nonsmokers (N = 9, 5.02 ± 4.87 IU/ml,
p=0.72). There was a main effect for exercise in that the post-exercise values (N=10, 7.76
±1.40 IU/ml) were larger than pre-exercise values (N=10, 3.82 ± 0.65, p=0.003).
However, there was no main effect for smoking and no smoking x exercise interaction
(Figure 1). Average smoking habits are reported in Table 2.
Discussion
These data suggest that e-cigarette smoking does not affect resting or postexercise FVIII antigen. Although there is no comparable resting data on the coagulation
response in e-cigarettes smokers, our data does contrast what has been found in cigarette
smokers at rest, who exhibit higher levels of FVIII (144.63 IU/dL) and significantly
higher levels of plasma fibrinogen (249.4 ± 1.93 mg/dL) compared to non-smokers
(141.72 IU/dL, p=0.173, 244.4 ± 1.12 mg/dL, p<0.05) (17,32,19). These findings may be
influenced by smoking volume, however, as hypercoagulability, measured by platelet
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aggregation, is significantly higher in healthy adults who have smoked greater than 15
pack years, compared to those who have smoked 5-15 pack years (27). Furthermore,
those who smoke 20+ cigarettes a day, as compared to those who smoke 1-19 cigarettes a
day, have significantly higher fibrinogen levels (32). Our e-cigarette smokers had only
been smoking 21.49 ± 15 months for an average of 22.38 ± 10.95 days a month (Table 2).
Thus, the volume and/or duration of smoking may have not been sufficient to
substantially impact FVIII.
There is no conclusive evidence in the literature that smoking of any kind has an
impact on blood coagulation following exercise. In a male monozygotic twins study with
one twin smoking cigarettes for 20 pack years and the other a nonsmoker, fibrinogen
tended to be increased among cigarette smokers following exercise but FVIII was not
significantly different between the two groups (20). This FVIII finding is consistent with
our results, but does not lead to a clear conclusion on the impact e-cigarettes or smoking
in general has on blood coagulation, due to our small sample size. We did, however,
observe a main exercise effect on blood coagulation, as FVIII was elevated following
exercise in both groups. This is consistent with the literature, as FVIII activity and FVIII
antigen increase to a similar degree from acute exercise (3,31).
The known health risks of traditional cigarettes have been well documented, while
the risks of e-cigarettes still remain to be less understood. This has potentially contributed
to increased e-cigarette usage over the past decade. Although e-cigarettes have been
marketed as being a safer alternative to conventional cigarettes, e-cigarettes still release
nicotine and concentrated substances that increase the risk of a cardiovascular event (21).
Our study provides initial findings for a lack of hemostatic changes with e-cigarette
usage. Further evaluation of the impacts e-cigarettes have on hemostasis and other
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markers of cardiovascular health still need to be performed, however, as our study only
measured FVIII antigen. Other hemostatic markers, like fibrinogen, have been seen to be
positively associated with smoking status (4). Furthermore, when examining the effects
of e-vapor on hemostasis, there is an e-vapor induced increase in platelet activation that
was independent of nicotine (14). This suggests that fine particulate matter from ecigarettes can lead to increased coagulability. E-cigarettes also lead to the largest levels
of high sensitive c-reactive protein when compared to both nonsmokers and cigarette
smokers (22), indicating an increased level of oxidative stress and inflammation similarly
found in smokers (33) which can further increase risk for CVD. The correlation between
this increase in inflammation found in e-cigarette users and any changes in hemostatic
markers has yet to be examined. However, the nicotine (23), aerosol (25), and particulate
matter (25) in e-cigarettes have all been found to influence individual risks of CVD.
Our study did have some major limitations that could have impacted our findings.
Definitive conclusions cannot be made because of our low sample size and the
inappropriate analysis of FVIII in samples that exceed the highest standard ELISA kit.
This makes our findings preliminary, however, they can potentially be used for sample
size calculations for future studies evaluating the effect size of e-cigarette use on
hemostasis. Further limitations include the non-standardization of both smoking duration
and smoking vessel, making it difficult to draw specific conclusions from our
participants. However, the diversity in our e-cigarette smoking pool is more
representative of the smoking population as a whole who typically smoke various brands
and have varying durations of active smoking. Finally, we did not investigate the
different in e-cigarette compositions that can potentially alter hemostasis. To better
understand the potential mechanisms e-cigarettes have on CVD risk and to further
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identify differences between e-cigarettes and conventional cigarettes, future studies
should isolate the compounds and report their effects.
In conclusion, our preliminary data suggests that e-cig use does not significantly
affect FVIII or the FVIII response to exercise.
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Figure 1. Pre and Post-Exercise Values of Factor VIII (FVIII) Antigen in Smokers and
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Figure Legend
Table 1. Subject Demographics between Women and Men in Smokers and Non-smokers
*-Significantly different than non-smoking women, p=0.003
Table 2. Average Smoking Habits of E-Cigarette Smokers
Figure 1. Pre and Post-Exercise Values of Factor VIII (FVIII) Antigen in Smokers and
Nonsmokers
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Chapter IV
Appendices
Appendix A
Informed Consent
Project Title: The impact of varying physical activity levels on airway inflammation,
airway hyperresponsiveness and hemostasis in e-cigarette smokers

Consent to Participate in Research
Identification of Investigators and Purpose of Study

You are being asked to participate in a research study conducted by Drs.
Stephanie Kurti and Christopher Womack from James Madison University. To
participate, you must be an electronic cigarette user or nonsmoker with no previous
history of cardiovascular, renal, and metabolic disease. The purpose of this study is to
determine if varying physical activity levels in e-cigarette users impacts airway
inflammation, airway hyperresponsiveness, and hemostasis. Previous research has shown
that e-cigarette use results in lower lung function compared to nonsmokers, but the
degree of lung function is much lesser compared to exclusive conventional tobacco
cigarette users. Moreover, exclusive conventional tobacco cigarette use increases blood
coagulation and decreases fibrinolysis compared to nonsmokers, but no investigation has
looked at e-cigarette use. Therefore our aim is to determine whether e-cigarette use is
causing damage to the airways before pulmonary function decline is observed as well the
impact it has on hemostatic variables at varying physical activity levels. This study will
contribute to the knowledge of both practitioners and clinicians, and may provide an
important public health message in providing recommendations for physical activity
levels that would have a protective effect in those who smoke e-cigarettes and/or
conventional tobacco cigarettes chronically. Should you decide to participate in this
research study, you will be asked to sign this consent form once all your questions have
been answered to your satisfaction.

Research Procedures
This study consists of questionnaires, a body composition scan, tracking physical
activity, one VO peak tests, pulmonary function tests, exhaled gas measurements, and
hypertonic saline challenges which will be administered to individual participants in the
Human Performance Laboratory at James Madison University.
The specific procedures during each visit are included here:
Initial visit: On the first visit to the laboratory, a researcher will go over informed
consent with you as well as begin the process of completing all questionnaires including
the international physical activity questionnaire, and the Physical Activity Readiness
questionnaire-Plus, and tobacco use questionnaire.
After completion of the questionnaires, we will obtain your height, weight, waist
circumference, and DEXA scan measurements to assess your body composition.You will
then perform an incremental exercise test to exhaustion on a cycle ergometer.
2
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Ventilatory, metabolic and heart rate data will be recorded for the entirety of the test until
you reach volitional fatigue at which the test will be terminated. Before and after the
exercise testing session, you will perform standard pulmonary function tests 2 minutes
and 10 minutes after the bout of exercise. Upon completion of the exercise session, you
will be given an accelerometer to wear for one week, which will you return on your
second visit.
Incremental exercise test to exhaustion: You will ride on an electronically
braked cycle ergometer approximately 12-15 minutes to determine VO . Your resting
metabolic measurements will be taken for 3 minutes prior to starting the test. You will
begin the test with a 2 minute warm-up, pedalling at 50 revolutions per minute at work
rate of 50 watts. Work rate will increase each minute by 10 watts for females and 20
watts for males. Your ventilatory and metabolic data will be recorded through breath by
breath analysis. Your heart rate will be recorded during and throughout the test with a
heart rate monitor and chest strap. A pulse oximeter will be secured to your left earlobe to
estimate arterial oxygen saturation. After each stage of the test, you will be asked to
report your RPE (rating of perceived exertion) as well as how difficult breathing feels to
you(sensation of dyspnea). The VO2 test will be terminated when you can no longer
continue exercise or maintain 50 revolutions/minute pedal frequency and have reached
volitional fatigue. You may end the test whenever you want if you feel uncomfortable.
Initial blood samples will be repeated at the end of the exercise test, within two minutes
of ending the exercise.
Pulmonary function tests: You will perform a maximum flow-volume loop
where you maximally inhale, forcefully exhale for 6 seconds and then maximally inhale
into a spirometer while wearing a nose-clip. This will record forced expiratory volume in
one-second, forced vital capacity, forced expiratory flow between 25 and 75% of forced
vital capacity , and peak expiratory flow. Then using impulse oscillometry, you will
breathe normally on a mouthpiece while the machine records resistance in your airway.
Finally you will be asked to take a brief, maximal inhale at the end of a normal breath for
every stage of the test. This is an experimental test to determine whether the you are
experiencing expiratory flow limitation during exercise. It is a simple breathing maneuver
that poses no risk to you.
Accelerometry: You will be asked to wear an accelerometer for 7 days around
your waist to track your physical activity. A researcher will guide you on how to
appropriately place the accelerometer on.
Second and third visit: You will come into the laboratory in the morning after an
overnight fast at which your blood pressure will be taken and 10 mL of your blood will
be collected via a serial venipuncture in the antecubital vein. Then you will exhale into a
nitric oxide analyzer for 6 seconds two times to measure your exhaled nitric oxide as a
measure of airway inflammation. You will then perform standard pulmonary function
testing via the maximum flow volume loop. Following this, you will perform both the
hypertonic saline challenge and hypertonic saline challenge with deep inspirations each
on different days for 20 minutes, and then perform pulmonary function testing
immediately after.
Hypertonic saline challenge session: You will breathe in 25% hypertonic saline
(salt and water) from an over-the-counter ultrasonic nebulizer that converts the salt
solution from a liquid to a mist. You will breathe normally on the nebulizer for 20
minutes while seated comfortably and wearing a nose clip.
2peak

peak

32
Hypertonic saline challenge with deep inspiration session: You will complete
the exact same protocol as the hypertonic saline challenge session plus perform 5 deep
inspirations immediately after the hypertonic saline challenge and prior to the pulmonary
function tests.

Risks

Participation in this study does have some small risks. The risk of any serious event
during this study is minimal. Possible risks include:
Hypertonic saline challenge: You may experience irritation, coughing,
wheezing, and/or bronchoconstriction (may be like asthma-like symptom in severe cases)
after inhaling this saline solution.
Venipuncture: You may experience mild bruising, risk of transfer of blood borne
pathogens, infection, and/or skin irritation when blood is taken intravenously.
DEXA: The DEXA scan entails a low dose of radiation equivalent to
approximately one transatlantic flight (0.015 mSv= milliseievert). While there is no
validated questionnaire to define extensive exposure, radiation exposure is cumulative
over the lifespan (200 DEXA scans is equal to the cumulative exposure of living at sea
level for a year (3 mSv). DEXA scans carry minimal X-ray exposure. To minimize
exposure, the DEXA scan will only be performed once. All body composition assessment
will be performed according to the American College of Sports Medicine guidelines for
body composition assessment.

Benefits

By participating in this study, you will learn about your current pulmonary health and
function (airway inflammation, airway hyperresponsive, forced expiratory flow in onesecond, forced vital capacity, forced expiratory flow at 25-75% of vital capacity),
VO peak, and body composition. Your data will be provided to you upon completion of
your participation in the study. If an emergency arises and you must dropout, you may
still receive your data.
2

Society will benefit from more knowledge about how e-cigarette usage may influence
adverse vascular and pulmonary outcomes, as well as how lifestyle may influence these
outcomes.

Confidentiality

The results of this project will be coded in such a way that the respondent’s identity will
not be attached to the final form of this study. The researcher retains the right to use and
publish non-identifiable data. While individual responses are confidential, aggregate data
will be presented representing averages or generalizations about the responses as a
whole. All data will be stored in a secure location accessible only to the JMU
researchers. Upon completion of the study, all information that matches up individual
respondents with their answers will be destroyed.

Participation & Withdrawal
Your participation is entirely voluntary. You are free to choose not to participate.
Should you choose to participate, you can withdraw at any time without consequences of
any kind.
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Questions about the study
If you have questions or concerns during the time of your participation in this study, or
after its completion or you would like to receive a copy of the final aggregate results of
this study, please contact:
Researcher’s Name: Dr. Stephanie Kurti
Email Address: kurtisp@jmu.edu

Department of Kinesiology
James Madison University

Cell-Phone number: 630-205-6363
Telephone: 540-568-3947
Researcher’s Name: Dr. Christopher Womack
Email Address: womackcx@jmu.edu

Department of Kinesiology
James Madison University

Telephone: 540-658-6145

Questions about Your Rights as a Research Subject
Dr. David Cockley
Chair, Institutional Review Board
James Madison University
(540) 568-2834
cocklede@jmu.edu

Giving of Consent
I have read this consent form and I understand what is being requested of me as a
participant in this study. I freely consent to participate. I have been given satisfactory
answers to my questions. The investigator provided me with a copy of this form. I
certify that I am at least 18 years of age.
______________________________________
Name of Participant (Printed)
______________________________________
Name of Participant (Signed)

______________
Date

______________________________________
Name of Researcher (Signed)

______________
Date
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Appendix B
The Physical Activity Readiness Questionnaire
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Tobacco Use Questionnaire
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